Guidelines to antiretroviral drug therapy in Kenya: Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...]
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Nairobi
National AIDS and STD Control Programme
2001
|
| Ausgabe: | 1. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | X, 65 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV019776914 | ||
| 003 | DE-604 | ||
| 005 | 20060110 | ||
| 007 | t | ||
| 008 | 050418s2001 ke d||| ||||z00||| eng d | ||
| 010 | |a 2002375277 | ||
| 035 | |a (OCoLC)53059758 | ||
| 035 | |a (DE-599)BVBBV019776914 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a ke |c KE | ||
| 049 | |a DE-703 | ||
| 050 | 0 | |a RA643.7.K4 | |
| 084 | |a MS 6410 |0 (DE-625)123754: |2 rvk | ||
| 245 | 1 | 0 | |a Guidelines to antiretroviral drug therapy in Kenya |b Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Nairobi |b National AIDS and STD Control Programme |c 2001 | |
| 300 | |a X, 65 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a AIDS (Disease) |x Chemotherapy |z Kenya | |
| 650 | 4 | |a AIDS (Disease) |x Treatment |z Kenya | |
| 650 | 4 | |a Acquired Immunodeficiency Syndrome |x drug therapy |z Kenya |v Practice Guideline | |
| 650 | 4 | |a Antiretroviral Therapy, Highly Active |z Kenya |v Practice Guideline | |
| 650 | 4 | |a Antiviral agents |z Kenya | |
| 650 | 4 | |a Chemotherapy, Combination |z Kenya | |
| 650 | 4 | |a HIV Infections |x drug therapy |z Kenya |v Practice Guideline | |
| 650 | 0 | 7 | |a Drogentherapie |0 (DE-588)4122122-9 |2 gnd |9 rswk-swf |
| 651 | 7 | |a Kenia |0 (DE-588)4030236-2 |2 gnd |9 rswk-swf | |
| 655 | 2 | |a Practice Guideline | |
| 689 | 0 | 0 | |a Kenia |0 (DE-588)4030236-2 |D g |
| 689 | 0 | 1 | |a Drogentherapie |0 (DE-588)4122122-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Chebet, Kenneth L. |e Sonstige |4 oth | |
| 710 | 2 | |a Kenia |b Ministry of Health |e Sonstige |0 (DE-588)502919-3 |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013102953&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-013102953 | ||
Datensatz im Suchindex
| _version_ | 1804133259281432576 |
|---|---|
| adam_text | CONTENTS
FOREWORD v
ACKNOWLEDGMENTS vi
INTRODUCTION I
CHAPTER ONE : Overview of antiretroviral Drugs I
CHAPTER TWO : Monitoring and Changing Therapy 14
CHAPTER THREE : Pharmacotherapeutics of ARVS 22
CHAPTER FOUR : Use of ARVS in Paediatric HIV Infection 31
CHAPTER FIVE : Infected Pregnant Women and
Prevention of Mother to Child
Transmission of HIV Infection 37
CHAPTER SIX : Post Exposure Prophylaxis 42
CHAPTER SEVEN : Special Considerations 44
CHAPTER EIGHT : When to Stop Treatment 47
CHAPTER NINE : Access to ARV Drugs in Kenya 55
APPENDIX 56
REFERENCE 66
TABLE OF CONTENTS
CHAPTER I INITIATING ANTIRETROVIRAL THERAPY
1.1 Introduction
1.2. Guidelines to making diagnosis of HIV infection ¦*
1 3 Laboratory Diagnosis
1.4 Goals of therapy **
1.5 When to start 5
1.6 Early versus delayed treatment: risks and benefits °
1.7 Antiretroviral profile
1.8 What drug combination to start with
CHAPTER 2 MONITORING AND CHANGING THERAPY 14
2.1 Surrogate markers 14
2.2 Resistance testing 15
2.3 Frequency 16
2.4 Treatment failure 16
2.5 Reasons for non adherence 17
2.6 Considerations for changing failure regimen 17
2.7 Guidelines for changing an ARV regimen 19
2.8 Potential options for changing therapy 20
CHAPTER 3 PHARMACOTHERAPEUTICS OF ARVS 22
3.1 Characteristics of available ARVS 22
3.2 Pharmacokinetic properties of Antiretrovirals 28
CHAPTER 4 GUIDELINES FOR USE OF ARVS IN
PAEDIATRIC HIV INFECTION 31
4.1 Overview 31
4.2 Diagnosis of HIV infection in children 31
4.3 When to initiate treatment 32
4.4 Initiation of treatment 33
4.5 Agents to choose for initial treatment 33
4.6 Dosages for pediatric formulations 33
4.7 Choice of new ARV drug 36
4.8 Monitoring 36
4.9 When to change therapy 36
CHAPTER 5 MANAGEMENT OF HUMAN IMMUNO
DEFICIENCY VIRUS INFECTED PREGNANT
WOMEN AND PREVENTION OF MOTHER
TO CHILD TRANSMISSION OF HIV INFECTION 37
5.1 Overview 37
5.2 Factors affecting mother to child transmission 38
5.3 Outline of antenatal, intrapartum, postpartum and
postnatal care 39
5.4 Antiretroviral Therapy to prevent MTCT 40
CHAPTER 6 SPECIAL CONSIDERATIONS 42
6.1 Acute retroviral syndrome 42
6.2 Tuberculosis 43
6.3 Immune recovery syndrome 43
CHAPTER 7 INTERRUPTION OF ARV 44
7.1 Structured treatment interruptions 44
7.2 Non structured treatment interruptions 46
CHAPTER 8 GUIDELINES FOR POST EXPOSURE
PROPHYLAXIS 47
8.1 Treatment of exposure site 47
8.2 Timing of post HIV exposure prophylaxis initiation 47
8.3 Assessment of exposure risk 47
8.4 Post HIV exposure prophylaxis 48
8.5 Recommended HIV serology after exposure 48
8.6 Management of health care workers 48
8.7 Management of hospital staff with sharps injury, exposure
to Blood and body fluids 51
8.8 Management of non occupational exposure to HIV infection 58
8.9 Management of non sexual and non occupational exposure to HIV 54
CHAPTER 9 ACCESS TO ARV DRUGS IN KENYA 55
APPENDIX 56
REFERENCES 66
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV019776914 |
| callnumber-first | R - Medicine |
| callnumber-label | RA643 |
| callnumber-raw | RA643.7.K4 |
| callnumber-search | RA643.7.K4 |
| callnumber-sort | RA 3643.7 K4 |
| callnumber-subject | RA - Public Medicine |
| classification_rvk | MS 6410 |
| ctrlnum | (OCoLC)53059758 (DE-599)BVBBV019776914 |
| discipline | Soziologie |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01927nam a2200481zc 4500</leader><controlfield tag="001">BV019776914</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20060110 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">050418s2001 ke d||| ||||z00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2002375277</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)53059758</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV019776914</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">ke</subfield><subfield code="c">KE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-703</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RA643.7.K4</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MS 6410</subfield><subfield code="0">(DE-625)123754:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Guidelines to antiretroviral drug therapy in Kenya</subfield><subfield code="b">Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Nairobi</subfield><subfield code="b">National AIDS and STD Control Programme</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 65 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS (Disease)</subfield><subfield code="x">Chemotherapy</subfield><subfield code="z">Kenya</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS (Disease)</subfield><subfield code="x">Treatment</subfield><subfield code="z">Kenya</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acquired Immunodeficiency Syndrome</subfield><subfield code="x">drug therapy</subfield><subfield code="z">Kenya</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiretroviral Therapy, Highly Active</subfield><subfield code="z">Kenya</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral agents</subfield><subfield code="z">Kenya</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy, Combination</subfield><subfield code="z">Kenya</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HIV Infections</subfield><subfield code="x">drug therapy</subfield><subfield code="z">Kenya</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Drogentherapie</subfield><subfield code="0">(DE-588)4122122-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Kenia</subfield><subfield code="0">(DE-588)4030236-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Practice Guideline</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kenia</subfield><subfield code="0">(DE-588)4030236-2</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Drogentherapie</subfield><subfield code="0">(DE-588)4122122-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chebet, Kenneth L.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Kenia</subfield><subfield code="b">Ministry of Health</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)502919-3</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013102953&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-013102953</subfield></datafield></record></collection> |
| genre | Practice Guideline |
| genre_facet | Practice Guideline |
| geographic | Kenia (DE-588)4030236-2 gnd |
| geographic_facet | Kenia |
| id | DE-604.BV019776914 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T20:05:52Z |
| institution | BVB |
| institution_GND | (DE-588)502919-3 |
| language | English |
| lccn | 2002375277 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-013102953 |
| oclc_num | 53059758 |
| open_access_boolean | |
| owner | DE-703 |
| owner_facet | DE-703 |
| physical | X, 65 S. graph. Darst. |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | National AIDS and STD Control Programme |
| record_format | marc |
| spelling | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] 1. ed. Nairobi National AIDS and STD Control Programme 2001 X, 65 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier AIDS (Disease) Chemotherapy Kenya AIDS (Disease) Treatment Kenya Acquired Immunodeficiency Syndrome drug therapy Kenya Practice Guideline Antiretroviral Therapy, Highly Active Kenya Practice Guideline Antiviral agents Kenya Chemotherapy, Combination Kenya HIV Infections drug therapy Kenya Practice Guideline Drogentherapie (DE-588)4122122-9 gnd rswk-swf Kenia (DE-588)4030236-2 gnd rswk-swf Practice Guideline Kenia (DE-588)4030236-2 g Drogentherapie (DE-588)4122122-9 s DE-604 Chebet, Kenneth L. Sonstige oth Kenia Ministry of Health Sonstige (DE-588)502919-3 oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013102953&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] AIDS (Disease) Chemotherapy Kenya AIDS (Disease) Treatment Kenya Acquired Immunodeficiency Syndrome drug therapy Kenya Practice Guideline Antiretroviral Therapy, Highly Active Kenya Practice Guideline Antiviral agents Kenya Chemotherapy, Combination Kenya HIV Infections drug therapy Kenya Practice Guideline Drogentherapie (DE-588)4122122-9 gnd |
| subject_GND | (DE-588)4122122-9 (DE-588)4030236-2 |
| title | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_auth | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_exact_search | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_full | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_fullStr | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_full_unstemmed | Guidelines to antiretroviral drug therapy in Kenya Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| title_short | Guidelines to antiretroviral drug therapy in Kenya |
| title_sort | guidelines to antiretroviral drug therapy in kenya republic of kenya ministry of health ed chebet k l |
| title_sub | Republic of Kenya, [Ministry of Health]. [Ed. Chebet K. L. ...] |
| topic | AIDS (Disease) Chemotherapy Kenya AIDS (Disease) Treatment Kenya Acquired Immunodeficiency Syndrome drug therapy Kenya Practice Guideline Antiretroviral Therapy, Highly Active Kenya Practice Guideline Antiviral agents Kenya Chemotherapy, Combination Kenya HIV Infections drug therapy Kenya Practice Guideline Drogentherapie (DE-588)4122122-9 gnd |
| topic_facet | AIDS (Disease) Chemotherapy Kenya AIDS (Disease) Treatment Kenya Acquired Immunodeficiency Syndrome drug therapy Kenya Practice Guideline Antiretroviral Therapy, Highly Active Kenya Practice Guideline Antiviral agents Kenya Chemotherapy, Combination Kenya HIV Infections drug therapy Kenya Practice Guideline Drogentherapie Kenia Practice Guideline |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013102953&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT chebetkennethl guidelinestoantiretroviraldrugtherapyinkenyarepublicofkenyaministryofhealthedchebetkl AT keniaministryofhealth guidelinestoantiretroviraldrugtherapyinkenyarepublicofkenyaministryofhealthedchebetkl |